Ken Griffin
KYNB

Ken Griffin’s Kyntra Bio KYNB Stock Holding History

Ken Griffin’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,756
Closed -$147K – 13339
2025
Q4 		$147K Sell
16,756
-6,761
-29% -$66.1K ﹤0.01% 11338
2025
Q3 		$288K Buy
+23,517
New +$221K ﹤0.01% 10478
2024
Q4 		– Sell
-7,722
Closed -$71.8K – 14761
2024
Q3 		$77.1K Buy
7,722
+4,339
+128% +$65.5K ﹤0.01% 11454
2024
Q2 		$75.5K Sell
3,383
-77,168
-96% -$2.38M ﹤0.01% 11277
2024
Q1 		$4.73M Sell
80,551
-15,076
-16% -$649K ﹤0.01% 4029
2023
Q4 		$2.12M Buy
95,627
+45,609
+91% +$688K ﹤0.01% 5258
2023
Q3 		$1.08M Buy
50,018
+38,499
+334% +$1.51M ﹤0.01% 6408
2023
Q2 		$778K Sell
11,519
-11,626
-50% -$4.81M ﹤0.01% 6985
2023
Q1 		$10.8M Sell
23,145
-157
-0.7% -$83.1K ﹤0.01% 2710
2022
Q4 		$9.33M Buy
23,302
+22,260
+2,136% +$8.53M ﹤0.01% 2933
2022
Q3 		$339K Sell
1,042
-2,479
-70% -$798K ﹤0.01% 9300
2022
Q2 		$930K Buy
3,521
+2,306
+190% +$589K ﹤0.01% 7191
2022
Q1 		$365K Sell
1,215
-11,229
-90% -$3.91M ﹤0.01% 10138
2021
Q4 		$4.39M Buy
+12,444
New +$3.87M ﹤0.01% 4561
2021
Q3 		– Sell
-307
Closed -$109K – 14033
2021
Q2 		$204K Sell
307
-799
-72% -$460K ﹤0.01% 12115
2021
Q1 		$960K Sell
1,106
-1,475
-57% -$1.57M ﹤0.01% 8226
2020
Q4 		$2.39M Sell
2,581
-3,454
-57% -$3.63M ﹤0.01% 4982
2020
Q3 		$6.2M Buy
6,035
+2,211
+58% +$2.38M ﹤0.01% 2860
2020
Q2 		$3.88M Buy
3,824
+2,351
+160% +$2.18M ﹤0.01% 3447
2020
Q1 		$1.28M Sell
1,473
-3,029
-67% -$3.01M ﹤0.01% 4905
2019
Q4 		$4.83M Sell
4,502
-9,085
-67% -$9.28M ﹤0.01% 3128
2019
Q3 		$12.6M Sell
13,587
-16,120
-54% -$17.7M 0.01% 1955
2019
Q2 		$33.6M Buy
29,707
+27,966
+1,606% +$30.6M 0.02% 988
2019
Q1 		$2.37M Sell
1,741
-504
-22% -$684K ﹤0.01% 4180
2018
Q4 		$2.6M Buy
+2,245
New +$2.52M ﹤0.01% 3743
2018
Q3 		– Sell
-221
Closed -$340K – 9351
2018
Q2 		$346K Sell
221
-147
-40% -$192K ﹤0.01% 6970
2018
Q1 		$426K Sell
368
-2,122
-85% -$2.79M ﹤0.01% 6176
2017
Q4 		$2.95M Buy
2,490
+1,648
+196% +$2.07M ﹤0.01% 3114
2017
Q3 		$1.13M Buy
842
+574
+214% +$605K ﹤0.01% 4142
2017
Q2 		$216K Sell
268
-534
-67% -$372K ﹤0.01% 6445
2017
Q1 		$494K Sell
802
-962
-55% -$586K ﹤0.01% 5033
2016
Q4 		$944K Sell
1,764
-3,881
-69% -$1.94M ﹤0.01% 3937
2016
Q3 		$2.92M Buy
5,645
+927
+20% +$437K ﹤0.01% 2526
2016
Q2 		$1.94M Buy
+4,718
New +$2.16M ﹤0.01% 2786
2016
Q1 		– Sell
-256
Closed -$128K – 7133
2015
Q4 		$195K Sell
256
-4,719
-95% -$3.13M ﹤0.01% 5839
2015
Q3 		$2.73M Buy
4,975
+3,904
+365% +$2.37M ﹤0.01% 2574
2015
Q2 		$629K Buy
1,071
+793
+285% +$461K ﹤0.01% 4623
2015
Q1 		$218K Buy
+278
New +$216K ﹤0.01% 6076

Other funds holding KYNB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Ken Griffin's KYNB Position: Q1 2026 in Review

Ken Griffin sold out of Kyntra Bio (KYNB) in Q1 2026, closing a stake of 16,756 shares — an estimated $147K sold.

Ken Griffin first reported a position in KYNB in Q1 2015 and held it in 38 quarters. The position peaked at $33.6M in Q2 2019. 32 funds tracked by Wall St. Rank hold KYNB as of Q1 2026.

  • Ken Griffin reported no remaining Kyntra Bio position as of Q1 2026 after selling out during the quarter.
  • Ken Griffin sold 16,756 Kyntra Bio shares in Q1 2026, an estimated $147K.
  • Ken Griffin first reported a position in Kyntra Bio in Q1 2015 and held it in 38 quarters.
  • Ken Griffin's Kyntra Bio position peaked at $33.6M in Q2 2019.
  • 32 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.